---
document_datetime: 2024-08-30 12:21:25
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pazenir-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: pazenir-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.2879347
conversion_datetime: 2025-12-19 21:35:33.563681
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pazenir

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                               |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0015               | Renewal of the marketing authorisation. | 09/11/2023                          | 05/01/2024                                  | PL                               | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pazenir in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0017/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/12/2023   | n/a   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IAIN/0016/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or | 12/09/2023   | n/a   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| amended PMF in the marketing of a medicinal product. (PMF Inclusion of an updated/amended do not affect the properties B.V.a.1.d - PMF - Inclusion amended PMF in the marketing of a medicinal product. (PMF Inclusion of an updated/amended do not affect the properties B.V.a.1.d - PMF - Inclusion amended PMF in the marketing of a medicinal product. (PMF Inclusion of an updated/amended do not affect the properties B.V.a.1.d - PMF - Inclusion amended PMF in the marketing of a medicinal product. (PMF Inclusion of an updated/amended do not affect the properties B.V.a.1.d - PMF - Inclusion amended PMF in the marketing of a medicinal product. (PMF Inclusion of an updated/amended do not affect the properties B.V.a.1.d - PMF - Inclusion amended PMF in the marketing of a medicinal product. (PMF Inclusion of an updated/amended do not affect the properties B.V.a.1.d - PMF - Inclusion amended PMF in the marketing   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                            |            |     | Inclusion of an   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| II/0014   | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                               | 25/05/2023 | n/a |                   |
| IA/0013/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 28/02/2023 | n/a |                   |

<div style=\"page-break-after: always\"></div>

|           | from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------|
| IB/0012   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/07/2022 | n/a        |                                  |         |
| IA/0011   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                     | 10/06/2022 | n/a        |                                  |         |
| IB/0010/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 09/03/2022 | 05/05/2022 | SmPC, Annex II, Labelling and PL | the MAH |
| IA/0009/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                              | 06/12/2021 | n/a        |                                  |         |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| IB/0008 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/04/2021 | 05/05/2022 | SmPC                  |
| II/0007 | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/09/2020 | n/a        |                       |
| IB/0006 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                          | 11/06/2020 | 26/02/2021 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

| IB/0004   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                | 05/03/2020   | 26/02/2021   | SmPC, Labelling and PL   |                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------|
| IB/0005   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                          | 20/01/2020   | n/a          |                          |                     |
| IB/0003/G | This was an application for a group of variations. B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data) C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 13/11/2019   | 09/12/2019   | SmPC and PL              | the MAH             |
| IA/0002/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure in test procedure for the finished                                                                                                                                               | 28/08/2019   | n/a          |                          | B.II.d.2.a - Change |

<div style=\"page-break-after: always\"></div>

|        | product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |                     |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| T/0001 | Transfer of Marketing Authorisation                                                                                                                                  | 07/06/2019 | 08/07/2019 | SmPC, Labelling and |